Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Innovent Biologics's Debt-to-EBITDA or its related term are showing as below:
IVBXF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.48 Med: -0.95 Max: 6.93
Current: 1.87
During the past 10 years, the highest Debt-to-EBITDA Ratio of Innovent Biologics was 6.93. The lowest was -5.48. And the median was -0.95.
IVBXF's Debt-to-EBITDA is ranked worse than 57.05% of 298
companies
in the Biotechnology industry
Industry Median: 1.23
vs IVBXF: 1.87
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Innovent Biologics Debt-to-EBITDA Related Terms
Innovent Biologics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Innovent Biologics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IVBXF vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Innovent Biologics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Innovent Biologics (IVBXF) has a Debt-to-EBITDA of 4.77 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Innovent Biologics. According to the industry distribution chart, Innovent Biologics ranks #170 out of 298 companies in the Biotechnology industry, placing it in the top 57%.
Is Innovent Biologics' Debt-to-EBITDA too high?
Innovent Biologics' current Debt-to-EBITDA is 4.77. The Biotechnology industry median Debt-to-EBITDA is 1.23. Innovent Biologics' value of 4.77 is 287.8% above this industry median. Based on the distribution chart, Innovent Biologics ranks #170 out of 298 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Innovent Biologics has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innovent Biologics ranks #170 out of 298 companies for Debt-to-EBITDA. This places Innovent Biologics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.23. Innovent Biologics' value of 4.77 is 287.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.23, based on 298 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innovent Biologics's current Debt-to-EBITDA of 4.77 is 287.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Innovent Biologics. For the Biotechnology industry, the median Debt-to-EBITDA is 1.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innovent Biologics's current Debt-to-EBITDA is 4.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (IVBXF) is currently considered Modestly Undervalued. The stock's GF Value™ is $12.63, compared to a current price of $10.68 — trading 15.4% below its estimated fair value. The current Debt-to-EBITDA is 4.77 and 287.8% above the Biotechnology industry median of 1.23. Innovent Biologics' overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Innovent Biologics (IVBXF), the current Debt-to-EBITDA is 4.77 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innovent Biologics (IVBXF) Overvalued in 2026?
Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued.
The current stock price of $10.68 is trading 15.4% below its estimated GF Value™ of $12.63.
GuruFocus considers Innovent Biologics to be Modestly Undervalued.
Key valuation signals for IVBXF:
Debt-to-EBITDA: 4.77
GF Value™: $12.63 vs. price of $10.68 (15.4% below fair value)
Industry Position: 287.8% above the Biotechnology median (#170 of 298)
No single metric tells the full story. See the IVBXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
78GF Score
Get the complete analysis for IVBXF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVBXF has been successfully added to your 
